000 01239 a2200325 4500
005 20250517110455.0
264 0 _c20180813
008 201808s 0 0 eng d
022 _a1433-2981
024 7 _a10.1016/j.clon.2016.07.004
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aJames, N D
245 0 0 _aResponse to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et al.
_h[electronic resource]
260 _bClinical oncology (Royal College of Radiologists (Great Britain))
_c10 2016
300 _a666-7 p.
_bdigital
500 _aPublication Type: Letter; Comment
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
650 0 4 _aDocetaxel
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aNeutropenia
650 0 4 _aProstatic Neoplasms
650 0 4 _aTaxoids
700 1 _aSydes, M R
700 1 _aClarke, N W
700 1 _aRitchie, A W S
700 1 _aParmar, M K B
773 0 _tClinical oncology (Royal College of Radiologists (Great Britain))
_gvol. 28
_gno. 10
_gp. 666-7
856 4 0 _uhttps://doi.org/10.1016/j.clon.2016.07.004
_zAvailable from publisher's website
999 _c26283632
_d26283632